LUPKYNIS Strengthens Market Position as Demand for Lupus Nephritis Treatment Grows
As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential global expansion, it is well-positioned for steady market growth.
LAS VEGAS, May 8, 2025 /PRNewswire/ — DelveInsight's 'LUPKYNIS Market Size, Forecast, and Market Insight Report' highlights the details around LUPKYNIS, the first oral lupus nephritis-specific treatment, which has expanded the therapeutic arsenal. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of LUPKYNIS. The report also highlights the historical and forecasted sales from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Aurinia Pharmaceuticals/Otsuka Pharmaceutical's LUPKYNIS (voclosporin) Overview
LUPKYNIS (voclosporin) is an oral immunosuppressant classified as a calcineurin inhibitor (CNI), shown to improve both short- and long-term outcomes in adult patients with active lupus nephritis when used alongside standard immunosuppressive therapies. By targeting calcineurin, LUPKYNIS helps suppress cytokine activity, inhibits interleukin-2 (IL-2) production, and reduces T-cell driven immune responses.
Although the exact mechanism by which voclosporin inhibits calcineurin is not fully understood, it is known that lymphocyte activation increases intracellular calcium, which binds to calcineurin's regulatory site. This activates the calmodulin-binding catalytic subunit, leading to dephosphorylation and activation of the transcription factor NFATc (nuclear factor of activated T-cells, cytoplasmic). The drug's immunosuppressive effect results in decreased lymphocyte proliferation, reduced cytokine production, and lower expression of T-cell activation markers.
The recommended initial dose of LUPKYNIS is 23.7 mg twice daily. It should be used in conjunction with mycophenolate mofetil (MMF) and corticosteroids.
Drug Name
LUPKYNIS (voclosporin)
Molecule type
Small molecule
Developer
Aurinia Pharmaceuticals/Otsuka Pharmaceutical
Approval year
US: 2021; EU: 2022; JP: 2024
Primary Indication
Lupus nephritis
Mechanism of action
Calcineurin-inhibitor immunosuppressant
Route of administration
Oral
Learn more about LUPKYNIS projected market size for lupus nephritis @ LUPKYNIS Market Potential
Lupus nephritis is a serious and potentially life-threatening complication of systemic lupus erythematosus (SLE), affecting 40–60% of those diagnosed with the disease. It is typically characterized by symptoms such as hematuria (blood in the urine) and proteinuria (protein in the urine). This condition is more prevalent in women, particularly between the ages of 20 and 40. In 2023, the United States recorded the highest number of lupus nephritis cases among the 7MM, with approximately 211K cases, a figure projected to grow by 2034.
Treatment strategies for lupus nephritis depend on the kidney biopsy classification of the disease. Standard therapy often includes corticosteroids in combination with immunosuppressive drugs like cyclophosphamide, mycophenolate mofetil, azathioprine, and calcineurin inhibitors. Rituximab, a monoclonal antibody, is widely used, especially for patients with relapsing or treatment-resistant LN, due to its ability to reduce reliance on steroids.
Currently, there are only two FDA-approved medications for lupus nephritis: BENLYSTA (belimumab), available as an intravenous or subcutaneous formulation, and LUPKYNIS (voclosporin), a novel oral calcineurin inhibitor.
Leading pharmaceutical companies such as Novartis, AstraZeneca, Roche, and Kezar Life Sciences, among others, are actively developing innovative therapies that could redefine the treatment paradigm for lupus nephritis. The treatment landscape is rapidly evolving, shifting away from broad immunosuppression toward more precise, targeted approaches. Recent drug approvals and a strong pipeline of candidates highlight both advancements and the ongoing challenges in creating treatments that are effective, safe, and long-lasting.
Emerging therapies ranging from anti-CD20 antibodies and complement inhibitors to interferon-blocking agents and CAR-T cell therapies hold promise but must address key issues such as safety, sustained efficacy, and accessibility. As our understanding of the disease's underlying mechanisms continues to grow, the future of lupus nephritis treatment is expected to become increasingly personalized, offering renewed hope to patients battling this complex disorder.
Discover more about the lupus nephritis market in detail @ Lupus Nephritis Market Report
Emerging Competitors of LUPKYNIS
The developing pipeline for lupus nephritis treatments shows a growing variety of approaches. Multiple candidates, both in early and late stages of development, are underway, including ianalumab (VAY736) (Novartis), GAZYVA (obinutuzumab) (Roche), SAPHNELO (anifrolumab) (AstraZeneca), FABHALTA (iptacopan) (Novartis), ULTOMIRIS (ravulizumab) (AstraZeneca), as well as advanced cellular therapies like CABA-201 (Cabaletta Bio) and YTB323 (Novartis).
In March 2025, the FDA accepted a supplemental Biologics License Application based on data from the Phase III REGENCY trial, where obinutuzumab demonstrated a 46.4% Complete Renal Response (CRR), compared to 33.1% for placebo. Unlike previous anti-CD20 therapies such as rituximab, it provides enhanced B-cell depletion and is the first in its class to show efficacy in a randomized Phase III lupus nephritis trial. If approved, it will become the first CD20-targeted treatment specifically indicated for lupus nephritis, with anticipated sales of USD 400 million by 2034.
To know more about the number of competing drugs in development, visit @ LUPKYNIS Market Positioning Compared to Other Drugs
Key Milestones of LUPKYNIS
In September 2024, Japan's Ministry of Health approved it for Lupus Nephritis treatment alongside mycophenolate mofetil. In September 2022, the European Commission approved LUPKYNIS for active Class III, IV, or V Lupus Nephritis. In January 2021, Aurinia Pharmaceuticals received US FDA approval for LUPKYNIS to treat adult lupus nephritis patients in combination with immunosuppressive therapy.
Discover how LUPKYNIS is shaping the lupus nephritis treatment landscape @ LUPKYNIS Lupus
LUPKYNIS Market Dynamics
LUPKYNIS, developed by Aurinia Pharmaceuticals, is the first FDA-approved oral therapy specifically indicated for active lupus nephritis, a serious manifestation of systemic lupus erythematosus. Approved in January 2021 in the US, LUPKYNIS entered a previously underserved market where treatment was largely dependent on off-label use of immunosuppressants like mycophenolate mofetil and corticosteroids. The drug represents a significant advancement in lupus nephritis care, offering both improved efficacy and a better safety profile compared to existing options, especially in reducing proteinuria and preserving kidney function.
The market dynamics for LUPKYNIS are shaped by several key factors. On the positive side, there is a strong unmet medical need, a growing prevalence of lupus nephritis, and increasing physician awareness about early diagnosis and intervention. Moreover, LUPKYNIS benefits from a relatively high pricing strategy, supported by its novel mechanism and disease-modifying potential. Aurinia has also built a dedicated commercial infrastructure and patient support programs to drive uptake and adherence.
However, LUPKYNIS faces competitive and reimbursement challenges. One of the main competitors is BENLYSTA (belimumab) from GSK, which gained FDA approval for lupus nephritis in December 2020, just a month before LUPKYNIS. Benlysta has the advantage of brand recognition and a longer track record in treating systemic lupus. Additionally, payers have shown some hesitancy in approving LUPKYNIS due to its cost, requiring extensive prior authorizations and documentation of clinical need. Patient compliance also remains an issue, given the need for frequent monitoring of kidney function and drug levels.
Looking ahead, the market potential for LUPKYNIS will depend on its ability to expand its label, demonstrate long-term real-world effectiveness, and potentially enter international markets. Aurinia is also exploring lifecycle management strategies, including combination therapies and expanded indications. Partnerships or acquisitions could further boost market access and penetration. Overall, while LUPKYNIS is a pioneering therapy with strong clinical value, its commercial success will be defined by navigating payer landscapes, physician adoption, and sustained differentiation from competing therapies.
Dive deeper to get more insight into LUPKYNIS's strengths & weaknesses relative to competitors @ LUPKYNIS Market Drug Report
Table of Contents
1
Report Introduction
2
LUPKYNIS: Aurinia Pharmaceuticals/Otsuka Pharmaceutical
2.1
Product Overview
2.2
Other Development Activities
2.3
Clinical Development
2.4
Clinical Trials Information
2.5
Safety and Efficacy
2.6
Product Profile
2.7
Market Assessment
2.7.1
The 7MM Analysis
2.7.1.1
Cost Assumptions and Rebate
2.7.1.2
Pricing Trends
2.7.1.3
Analogue Assessment
2.7.1.4
Launch Year and Therapy Uptake
2.7.2
The United States Market Analysis
2.7.3
EU4 and the United Kingdom Market Analysis
2.7.3.1
Germany
2.7.3.2
France
2.7.3.3
Italy
2.7.3.4
Spain
2.7.3.5
UK
2.7.4
Japan Market Analysis
2.8
Market Drivers
2.9
Market Barriers
2.10
SWOT Analysis
3
Key Cross of Marketed Competitors of LUPKYNIS
4
Key Cross of Emerging Competitors of LUPKYNIS
Related Reports
Lupus Nephritis Market
Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, among others.
Lupus Nephritis Pipeline
Lupus Nephritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, among others.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Systemic Lupus Erythematosus Pipeline
Systemic Lupus Erythematosus Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lupkynis-strengthens-market-position-as-demand-for-lupus-nephritis-treatment-grows–delveinsight-302449679.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Michelle Monaghan Champions Skin Health in New Awareness Campaign
NEW YORK, May 30, 2025 /PRNewswire/ — Healthy skin is more than surface-level, it's a key part of our overall well-being. That's why Mediaplanet is proud to launch its 'Skin Health' campaign, aimed at empowering individuals to take charge of their skin through education, prevention, and smart skincare choices. From early detection to everyday sun protection, this campaign emphasizes that maintaining healthy skin is a lifelong commitment. Skin is our body's largest organ, yet it's often overlooked when it comes to proactive care. This campaign is designed to change that by delivering expert guidance, highlighting innovative dermatological advances, and sharing practical tips for every age and skin type. Whether you're managing a chronic condition or simply want to build better daily habits, the 'Skin Health' campaign offers resources to help you prioritize long-term skin wellness. Featuring cover story Michelle Monaghan, the campaign brings a personal and powerful voice to the conversation. The award-winning actress opens up about her experience with skin cancer, how motherhood reshaped her view on sun safety, and the importance of early detection. In her exclusive interview, Monaghan shares the simple yet critical habits she relies on — like daily sunscreen use and routine skin checks — while encouraging others to take their skin health seriously. The print component of 'Skin Health' is distributed in today's edition of USA Today. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: This campaign was made possible with the support of Michelle Monaghan, Jennie Garth, Dr. Charles, MD, Dr. Jenny Liu, M.D., FAAD, Dr. Lindsey Zubritsky, M.D., FAAD, Dr. Mamina Turegano, M.D., FAAD, the Skin Cancer Foundation, the American Society for Dermatologic Surgery, the Society for Pediatric Dermatology, the Society of Cosmetic Chemists, the Coalition of Skin Diseases, the National Foundation for Ectodermal Dysplasias and features paid content from the Melanoma Research Foundation, Castle Biosciences, GentleCure & Sciton.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
YONGIN, South Korea, May 30, 2025 /PRNewswire/ — GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period. Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly. The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly. In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters. The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life. In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease. Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy. 'This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase', said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. 'The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility.' 'We are thrilled to publish our encouraging phase 3 clinical trial results', stated Jae Uk Jeong, Head of R&D at GC Biopharma. 'Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome.' Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kimshkim20@ Yelin Junyelin@ Yoonjae Nayjy6520@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Rapid AI Karyotype Total Solution From China Makes a Big Splash
MILAN, Italy, May 30, 2025 /PRNewswire/ — From May 24 to 27, 2025, the annual conference of the European Society of Human Genetics (ESHG) 2025 held successfully in Milan, Italy. Hangzhou Diagens Biotechnology Co., Ltd. ( from China, made a stunning appearance with its rapid AI karyotype total solution, which received high recognition from the attending scholars. Diagens has developed the Rapid AI karyotype total solution based on iMedImage®, a globally leading general medical imaging model. This solution integrates an automatic cell harvester, a slide preparation and staining machine, an automatic cell microscopy scanning system, and an intelligent chromosome karyotyping analysis system. By leveraging four core advantages—full automation, in-depth informatization, pioneering intelligence, and unmanned processes—it has created a new type of unmanned smart laboratory. This laboratory achieves seamless 'sample input to report output' operations, significantly enhancing the speed and efficiency of sample processing and analysis while reducing laboratory costs. This advancement sets a new benchmark for the industry. During the conference, Professor Liang Desheng from the Center for Medical Genetics at Central South University in China presented a poster titled 'iMedImage®: an end-to-end foundational model for medical image recognition and its application in chromosome analysis.' Karyotyping, the gold standard for detecting chromosomal abnormalities, remains critical for diagnosing genetic and hereditary diseases. While AI effectively identifies numerical abnormalities, detecting structural abnormalities remains challenging. This abstract introduces iMedImage®, an innovative end-to-end foundation model for medical image recognition. When applied to chromosomal abnormality detection, iMedImage® demonstrated promising performance and significantly enhanced detection capabilities, achieving a diagnostic accuracy rate of 99.59%, sensitivity of 95.83%, and specificity of 100%. Additionally, the model demonstrates outstanding performance across multiple medical imaging fields, including cellular, pathological, ultrasound, X-ray, CT, and MRI, highlighting its broad application potential. The launch of Diagens rapid AI karyotype total solution represents a significant breakthrough in the intelligentization of cell experiments. It has received high acclaim from clients in Europe, Africa, South America, Asia, and other regions, with many expressing their intention to collaborate. This showcases Diagens' leading technology and innovation capabilities in the field of AI-driven healthcare. Looking ahead, Diagens will continue to adhere to the philosophy of innovation-driven development, constantly exploring cutting-edge technologies to contribute more Chinese power to the global healthcare cause. Learn more about Diagens and its solutions, please visit its website at or contact at sales@ Photo – View original content:
